Spectral announces first quarter 2009 results



    TORONTO, May 14 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a company
focused on bringing to market a diagnostic and a therapeutic targeting severe
sepsis, today announced its financial results for the first quarter ended
March 31, 2009.
    "This quarter, we achieved an important milestone by securing the
exclusive rights to develop and commercialize Toraymyxin(TM) for the US market
after thorough due diligence into the product and its potential market
opportunity," said Dr. Paul Walker, President and CEO of Spectral.
"Toraymyxin(TM) has been used on more than 70,000 patients to date, primarily
in Europe and Japan, for the treatment of severe sepsis and has demonstrated a
significant reduction in the mortality of patients with severe sepsis compared
to standard of care. We believe that, when used together with our proprietary
Endotoxin Activity Assay (EAA(TM)), Toraymyxin(TM) represents a significant
medical advance in helping doctors manage a devastating disease. Our next
steps will be to obtain an Investigational Device Exemption (IDE) from the US
FDA and to initiate a registration trial for Toraymyxin(TM) in 2009."

    
    First quarter 2009 highlights:

    -   Data on the clinical utility of EAA(TM) and Toraymyxin(TM) was
        featured in a key scientific symposium entitled, "The Role of
        Endotoxin," that included presentations from six thought leaders in
        the field of sepsis, at the 29th International Symposium on Intensive
        Care and Emergency Medicine in Brussels, Belgium in March.

    -   New findings demonstrating the clinical utility of EAA(TM) were
        presented at the 13th Annual Critical Care for Endotoxemia Congress.
        The conference took place in Tokyo, Japan in February.

    -   A final license and supply agreement was signed with Toray
        Industries, Inc. for the exclusive development and commercial rights
        in the U.S. for Toraymyxin(TM) in March.

    -   A preliminary meeting was held with the US FDA.
    

    Financial Review

    For the three months ended March 31, 2009, Spectral reported sales of
$842,000, compared to $664,000 for the corresponding period in 2008. This
represents a 27% increase. Sales in all product categories were higher due to
improved EAA(TM) diagnostic sales and the consistency of royalty revenues and
reagent sales related to the Company's proprietary Troponin I products.
    Operating expenses for the three months ended March 31, 2009 were
$1,043,000, compared to $976,000 for the corresponding period in 2009, due to
the continued maintenance of a low cost operating structure. These expenses
included $100,000 of costs related to the development of the Toraymyxin(TM)
clinical pathway.
    For the three months ended March 31, 2009, the Company reported a loss of
$404,000, or ($0.02) per share, compared to a loss of $448,000 or ($0.02) per
share for the corresponding period in 2008.
    Cash and short term investments as at March 31, 2009 totaled $4,053,000,
compared to $4,297,000 as at December 31, 2008. Management expects that the
Company will maintain a minimum cash and short term investment balance of
$3,000,000 for the rest of 2009.

    About Spectral Diagnostics

    Spectral is a leader in the battle against sepsis. Spectral's lead
product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay
for the measurement of endotoxin. With the growing awareness for the role of
endotoxemia in sepsis and the increasing number of therapies being developed
to treat endotoxemia, Spectral is well-positioned to promote the adoption of
the EAA(TM), which can be used to identify patients, enable therapeutics and
monitor treatment. Spectral is listed on TSX under the symbol SDI.

    Forward-looking statement

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    
    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.


    Spectral Diagnostics Inc.

    Balance Sheets - unaudited
    As at March 31, 2009 and December 31, 2008
    -------------------------------------------------------------------------

    (in thousands of dollars)
                                                            2009        2008
                                                               $           $
    Assets

    Current assets
    Cash and cash equivalents                                 16         297
    Short-term investments                                 4,037       4,000
    Accounts receivable                                      908         860
    Inventories                                              204         203
    Prepaid expenses                                         168          42
                                                     ------------------------

                                                           5,333       5,402

    Property, plant and equipment                            449         493

    Commercial instruments                                   133         132

    Purchased technology and trademarks                      941       1,058
                                                     ------------------------

                                                           6,856       7,085
                                                     ------------------------
                                                     ------------------------
    Liabilities

    Current liabilities
    Bank indebtedness                                        385           -
    Accounts payable and accrued liabilities                 332         540

    Deferred revenue                                         279         322

    Convertible notes payable                              2,213       2,172
                                                     ------------------------

                                                           3,209       3,034
                                                     ------------------------

    Shareholders' Equity

    Common shares                                          2,524       2,524

    Other equity                                           5,716       5,716

    Deficit                                               (4,593)     (4,189)
                                                     ------------------------

                                                           3,647       4,051
                                                     ------------------------

                                                           6,856       7,085
                                                     ------------------------
                                                     ------------------------


    Spectral Diagnostics Inc.

    Statements of Operations, Comprehensive Loss and Deficit - unaudited
    For the three months ended March 31, 2009 and 2008
    -------------------------------------------------------------------------
    (in thousands of dollars, except share and per share data)

                                                            2009        2008
                                                               $           $

    Sales                                                    842         664

    Cost of sales                                            184         200
                                                     ------------------------

    Gross margin                                             658         464
                                                     ------------------------

    Operating expenses
    Selling, general and administrative                      891         792
    Amortization                                             164         154
    Foreign exchange gain                                    (32)         (5)
    Stock-based compensation                                   -          21
    Research and product development,
     net of tax credits                                       20          14
                                                     ------------------------

                                                           1,043         976
                                                     ------------------------

    Loss before the following                               (385)       (512)

    Interest expense on convertible notes payable            (41)        (41)

    Other net interest income                                 22         105

                                                     ------------------------

    Loss and comprehensive loss  for the period             (404)       (448)

    Deficit - Beginning of period                         (4,189)     (2,687)

                                                     ------------------------

    Deficit - End of period                               (4,593)     (3,135)
                                                     ------------------------
                                                     ------------------------

    Basic and diluted loss  per common share               (0.02)      (0.02)
                                                     ------------------------
                                                     ------------------------

    Weighted average number of common
     shares outstanding                               24,118,424  24,118,424
                                                     ------------------------
                                                     ------------------------


    Spectral Diagnostics Inc.

    Statements of Cash Flows - unaudited
    For the three months ended March 31, 2009 and 2008
    -------------------------------------------------------------------------

    (in thousands of dollars)

                                                            2009        2008
                                                               $           $

    Cash provided by (used in)

    Operating activities
    Loss and comprehensive loss for the period              (404)       (448)
    Items not affecting cash
      Amortization                                           164         154
      Amortization of commercial instruments included
       in cost of sales                                       21           5
      Stock-based compensation expense                         -          21
      Interest on convertible notes payable                   41          41
    Changes in non-cash working capital                     (383)       (167)
                                                     ------------------------

                                                            (561)       (394)
                                                     ------------------------

    Investing activities
    Purchase of property, plant and equipment                 (3)        (14)
    Purchase of commercial instruments                       (22)        (22)
    Increase  in short-term investments                      (37)       (103)
    Decrease in deferred revenue                             (43)         (3)
                                                     ------------------------

                                                            (105)       (142)
                                                     ------------------------

    Financing activities
    Bank indebtedness                                        385           -
                                                     ------------------------

    Decrease in cash and cash equivalents
     during the period                                      (281)       (536)

    Cash and cash equivalents - Beginning of period          297         638
                                                     ------------------------

    Cash and cash equivalents - End of period                 16         102
                                                     ------------------------
                                                     ------------------------
    

    %SEDAR: 00002006E




For further information:

For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; Casey Gurfinkel, Investor Relations, (416) 815-0700 ext.
283, cgurfinkel@equicomgroup.com

Organization Profile

Spectral Diagnostics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890